Circulating tumor DNA (ctDNA) minimal residual disease (MRD) is a powerful biomarker
with the potential to improve survival outcomes for non–small-cell lung cancer (NSCLC) …

Abstract Background Circulating tumor DNA (ctDNA) has been proven as a marker for
detecting minimal residual diseases following systemic therapies in mid-to-late-stage non …

Circulating tumor DNA (ctDNA) has demonstrated great potential as a noninvasive
biomarker to assess minimal residual disease (MRD) and profile tumor genotypes in …

Advances in DNA sequencing methods have significantly expanded the potential clinical
applications of analyzing circulating tumor DNA (ctDNA). This genetic information can …

Circulating tumour DNA (ctDNA) refers to the fraction of cell-free DNA in a patient's blood
that originates from a tumour. Advances in DNA sequencing technologies and our …

Identifying molecular residual disease (MRD) after treatment of localized lung cancer could
facilitate early intervention and personalization of adjuvant therapies. Here, we apply cancer …

Background Identification of residual disease in patients with localized non-small cell lung
cancer (NSCLC) following treatment with curative intent holds promise to identify patients at …

Circulating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that
originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as …

Background Routine clinical surveillance involves serial radiographic imaging following
radical surgery in localized non-small cell lung cancer (NSCLC). However, such …

Introduction Minimal residual disease (MRD) detection in solid tumors describes isolation of
circulating tumor DNA (ctDNA) molecules in plasma following definitive treatment of a …